IntroductionNeuroendocrine neoplasms (NENs) are a rare group of tumors exceptionally heterogeneous, with clinical presentation ranging from well differentiated more indolent tumors to poorly differentiated very aggressive forms. Both are often diagnosed after the metastatic spread and require appropriate medical treatment. A high priority need in the management of this disease is the identification of effective therapeutic strategies for advanced and metastatic patients. The recent TALENT trial demonstrated the efficacy of lenvatinib, a multi-tyrosine kinase inhibitor, in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with no other treatment indication. Further development of this drug in advanced NETs is warranted. MethodsWe investigated potential clinical and molecular determinants of lenvatinib response in human primary cultures derived from patients with GEP-NET of different grades and sites of origin. We correlated response to treatment with patient clinical characteristics, with the mutational status of 161-cancer associated genes and with the expression levels of MKI-related genes. ResultsLenvatinib exerted a significant antitumor activity in primary GEP-NET cells, with median survival inhibitions similar or higher than those of standard frontline treatments. Of the 11 primary cultures analyzed in our case series, 6 were classified as responder showing a significant survival inhibition, and 5 as non-responder. We observed that the overexpression of HRAS in the original tumor tissue compared to the matched healthy tissue significantly correlated with responsiveness of primary cells to lenvatinib (p=.048). All 5 non-responder cultures showed normal HRAS expression, while of the 6 responder cultures, 4 had HRAS overexpression. Overexpression of HRAS was not associated with gene mutation. None of the other evaluated clinical variables (grade, Ki67, site of origin and syndromic disease) or molecular markers correlated with response. DiscussionLenvatinib appears to be a highly effective drug for the treatment of NETs. The evaluation of HRAS expression in the tumor tissue might improve patient selection and optimize therapeutic outcome.

HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors / Liverani, Chiara; Spadazzi, Chiara; Ibrahim, Toni; Pieri, Federica; Foca, Flavia; Calabrese, Chiara; De Vita, Alessandro; Miserocchi, Giacomo; Cocchi, Claudia; Vanni, Silvia; Ercolani, Giorgio; Cavaliere, Davide; Ranallo, Nicoletta; Chiadini, Elisa; Prisinzano, Giovanna; Severi, Stefano; Sansovini, Maddalena; Martinelli, Giovanni; Bongiovanni, Alberto; Mercatali, Laura. - In: FRONTIERS IN ENDOCRINOLOGY. - ISSN 1664-2392. - ELETTRONICO. - 13:2(2023), pp. 1045038.1-1045038.12. [10.3389/fendo.2022.1045038]

HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors

Spadazzi, Chiara
;
Calabrese, Chiara;De Vita, Alessandro;Cocchi, Claudia;Ercolani, Giorgio;Ranallo, Nicoletta;Chiadini, Elisa;Prisinzano, Giovanna;Sansovini, Maddalena;Martinelli, Giovanni;Mercatali, Laura
2023

Abstract

IntroductionNeuroendocrine neoplasms (NENs) are a rare group of tumors exceptionally heterogeneous, with clinical presentation ranging from well differentiated more indolent tumors to poorly differentiated very aggressive forms. Both are often diagnosed after the metastatic spread and require appropriate medical treatment. A high priority need in the management of this disease is the identification of effective therapeutic strategies for advanced and metastatic patients. The recent TALENT trial demonstrated the efficacy of lenvatinib, a multi-tyrosine kinase inhibitor, in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with no other treatment indication. Further development of this drug in advanced NETs is warranted. MethodsWe investigated potential clinical and molecular determinants of lenvatinib response in human primary cultures derived from patients with GEP-NET of different grades and sites of origin. We correlated response to treatment with patient clinical characteristics, with the mutational status of 161-cancer associated genes and with the expression levels of MKI-related genes. ResultsLenvatinib exerted a significant antitumor activity in primary GEP-NET cells, with median survival inhibitions similar or higher than those of standard frontline treatments. Of the 11 primary cultures analyzed in our case series, 6 were classified as responder showing a significant survival inhibition, and 5 as non-responder. We observed that the overexpression of HRAS in the original tumor tissue compared to the matched healthy tissue significantly correlated with responsiveness of primary cells to lenvatinib (p=.048). All 5 non-responder cultures showed normal HRAS expression, while of the 6 responder cultures, 4 had HRAS overexpression. Overexpression of HRAS was not associated with gene mutation. None of the other evaluated clinical variables (grade, Ki67, site of origin and syndromic disease) or molecular markers correlated with response. DiscussionLenvatinib appears to be a highly effective drug for the treatment of NETs. The evaluation of HRAS expression in the tumor tissue might improve patient selection and optimize therapeutic outcome.
2023
HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors / Liverani, Chiara; Spadazzi, Chiara; Ibrahim, Toni; Pieri, Federica; Foca, Flavia; Calabrese, Chiara; De Vita, Alessandro; Miserocchi, Giacomo; Cocchi, Claudia; Vanni, Silvia; Ercolani, Giorgio; Cavaliere, Davide; Ranallo, Nicoletta; Chiadini, Elisa; Prisinzano, Giovanna; Severi, Stefano; Sansovini, Maddalena; Martinelli, Giovanni; Bongiovanni, Alberto; Mercatali, Laura. - In: FRONTIERS IN ENDOCRINOLOGY. - ISSN 1664-2392. - ELETTRONICO. - 13:2(2023), pp. 1045038.1-1045038.12. [10.3389/fendo.2022.1045038]
Liverani, Chiara; Spadazzi, Chiara; Ibrahim, Toni; Pieri, Federica; Foca, Flavia; Calabrese, Chiara; De Vita, Alessandro; Miserocchi, Giacomo; Cocchi, Claudia; Vanni, Silvia; Ercolani, Giorgio; Cavaliere, Davide; Ranallo, Nicoletta; Chiadini, Elisa; Prisinzano, Giovanna; Severi, Stefano; Sansovini, Maddalena; Martinelli, Giovanni; Bongiovanni, Alberto; Mercatali, Laura
File in questo prodotto:
File Dimensione Formato  
2023-Liverani (front Oncol)-HRAS overexspression in pancreatic neuroendocrine tumor.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 4.17 MB
Formato Adobe PDF
4.17 MB Adobe PDF Visualizza/Apri
DataSheet_1.pdf

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 342.3 kB
Formato Adobe PDF
342.3 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/961500
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact